Therapy Detail

Therapy Name BAY1187982
Synonym
Therapy Description

BAY1187982 is an FGFR2 antibody conjugated to a toxin, which may promote apoptosis and inhibit tumor growth (NCI Drug Dictionary).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
BAY1187982 FGFR2-ADC FGFR2 Antibody 3 BAY1187982 is an FGFR2 antibody conjugated to a toxin, which may promote apoptosis and inhibit tumor growth (NCI Drug Dictionary).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
FGFR2 amp ovarian cancer sensitive BAY1187982 Preclinical - Pdx Actionable In a preclinical study, BAY1187982 inhibited tumor growth in patient-derived xenograft models of FGFR2 amplified ovarian cancer (PMID: 27543601). 27543601
FGFR2 dec exp breast cancer resistant BAY1187982 Preclinical - Cell culture Actionable In a preclinical study, BAY1187982 did not inhibit growth of breast cancer cells with very low Fgfr2 expression level in culture (PMID: 27543601). 27543601
FGFR2 positive breast cancer sensitive BAY1187982 Preclinical - Pdx & cell culture Actionable In a preclinical study, BAY1187982 inhibited survival of Fgfr2 positive breast cancer cell lines in culture, and suppressed tumor growth in both cell line and patient-derived xenograft models (PMID: 27543601). 27543601
FGFR2 over exp colorectal cancer sensitive BAY1187982 Preclinical - Cell line xenograft Actionable In a preclinical study, BAY1187982 inhibited survival of colorectal cancer cells with over expressing Fgfr2 in culture, and suppressed tumor growth in cell line xenograft models (PMID: 27543601). 27543601
FGFR2 positive Advanced Solid Tumor sensitive BAY1187982 Preclinical - Pdx & cell culture Actionable In a preclinical study, sensitivity to BAY1187982 positively correlated with Fgfr2 expression level in a variety of cancer cell lines in culture, and in cell line or patient-derived xenograft models (PMID: 27543601). 27543601
FGFR2 positive stomach cancer sensitive BAY1187982 Preclinical - Pdx & cell culture Actionable In a preclinical study, BAY1187982 inhibited survival of gastric cancer cell lines with elevated Fgfr2 expression level in culture, and suppressed tumor growth in cell line or patient-derived xenograft models (PMID: 27543601). 27543601
Clinical Trial Phase Therapies Title Recruitment Status
NCT02368951 Phase I BAY1187982 Phase I, Dose-escalation Trial of BAY1187982 in Subjects With Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2) Terminated